A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
Latest Information Update: 17 Oct 2024
At a glance
- Drugs SBT-77-7101 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Acronyms Regulate-HS
- Sponsors Sonoma Biotherapeutics
- 14 Oct 2024 Planned End Date changed from 1 Sep 2026 to 1 Nov 2026.
- 14 Oct 2024 Planned primary completion date changed from 1 Sep 2026 to 1 Nov 2026.
- 14 Oct 2024 Planned initiation date changed from 1 Sep 2024 to 1 Nov 2024.